OnQuality Announces FDA Clearance of IND Application for OQL025 for the treatment of EGFR Inhibitor-Induced Acneiform Rash
OnQuality Announces FDA Clearance of IND Application for OQL051
OnQuality Announces FDA Clearance of IND Application for OQL036
OnQuality Pharmaceuticals Presented Preclinical Data at the AACR Annual meeting
OnQuality Pharmaceuticals Announces Presentations of OQL025 and OQL06x, at the AACR Annual Meeting
OnQuality Pharmaceuticals Expands Part 2 of the NOVA-II Phase 2 Clinical Trial to China and India
Targeted Oncology First Patient With VEGFRi-Associated Hand-Foot Skin Reaction Enrolled in NOVA-II
Clinical Trials Arena I OnQuality enrols first subject in Phase II HFSR therapy trial
OnQuality Pharmaceuticals Announces Enrollment of First Patient in Part 2 of the NOVA-II Phase 2
OnQuality Pharmaceuticals to Present Two Posters at the 34th EORTC-NCI-AACR Symposium